Skip to main content
Home
  • STARTSEITE
  • ÜBER REACTIV8
  • FÜR KLINIKER
  • Über Mainstay
  • News & Events
  • FÜR INVESTOREN
  • Careers
  • Contact
  • EN
  • FR
  • DE
  • NL
  • US
  • AU
Sub menu▸
  • OVERVIEW
  • Results and Presentations
  • News
  • Governance
    • Corporate Governance
    • Board of Directors
    • Leadership Team
    • Board Committees
    • AGM
  • Share Price
  • Shareholder Information
  • Rule 26 Information
  • Contact Us

AGM

2019 AGM

  • Notice of 2019 Annual General Meeting
  • Annual Report for the year ended 31 December 2018

2018 AGM

Click here for more information ▾
  • Notice of 2018 Annual General Meeting
  • Annual Report for the year ended 31 December 2017

2017 AGM

Click here for more information ▾
  • Notice of 2017 Annual General Meeting
  • Annual Report for the year ended 31 December 2016
  • Amended Articles of Association

2016 AGM

Click here for more information ▾
  • Notice of 2016 Annual General Meeting
  • Annual Report for the year ended 31 December 2015

2015 AGM

Click here for more information ▾
  • Notice of 2015 Annual General Meeting
  • Annual Report for the year ended 31 December 2014
  • Amended Memorandum and Articles of Association
Last Updated on 13th August 2019

© Copyright 2017 Mainstay Medical Limited. Alle Rechte vorbehalten.

Footer menu

  • Plan der Website
  • Kontakt
  • Impressum
  • Datenschutz
  • Nutzungsbedingungen
  • Commercial Terms & Conditions

ReActiv8 ist für die Behandlung von chronischem unterem Rückenschmerz CE zertifiziert und ist in Europa für den Verkauf verfügbar.

Disclaimer

I am in the United States, Canada, Japan or Australia.

Show